Interventions should compare EGCG (bioavailable formulation) with PAR-2-selective antagonists/pepducins, mast-cell stabilisers, FXa inhibition, and pathway-selective (“biased”) PAR-2 modulators; exploratory modalities could include AAV-delivered dominant-negative PAR-2 in the heart or PROTAC-like degraders for tumour-PAR-2, with stringent safeguards to preserve anti-tumor efficacy. Here, F2RL1 is linked to neoplasm.